Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Traumakine (FP-1201-lyo, recombinant interferon beta-1a) vs placebo in moderate or severe ARDS
2014-005260-15Phase 3Terminated
- Sponsor
- Faron Pharmaceuticals
- Start
- Jul 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing FP-1201-lyo (Traumakine) with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jul 2015; status: terminated.
02
Drugs
interferon beta-1a
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2014-005260-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005260-15.